Testing ketamine for depression in adults with alcohol use disorder
Tests ketamine against a placebo for depression in adults with alcohol use disorder.
Plain-language title generated from the registry record
Registry title: Ketamine for depression and alcohol use disorder
Key facts
- Where
- Grålum and Tromsoe, NorwaySee the 2 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with at least moderate depression and alcohol dependence who are in hospital for addiction treatment.
- Age
- 18 to 65 years (the registry also lists a maximum age of 64 years)
- Sex
- All sexes can join.
- Disease stage
- At least moderate depression without psychotic features. Alcohol dependence is the main substance use problem.
- Earlier treatment
- Must be in the hospital for inpatient addiction therapy at University Hospital of North Norway. No illegal use of ketamine in the last 6 months.
Main reasons for not taking part
- Cannot give proper informed consent
- Past or current psychotic disorder
- Significant heart event in the last year
- Liver failure or reduced liver function
- Significant chronic kidney, heart or breathing failure
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT06090422, who can take part
Where in Norway
- Østfold Hospital TrustGrålum, NorwayTaking people
- Universitetssykehuset Nord-Norge HFTromsoe, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Of North Norway HF
- Trial code
- NCT06090422EU 2023-506052-24-00
- Record updated
- 17 July 2026
- Original description
The primary objective is to assess the efficacy of ketamine for depression in adults with depression and AUD that are admitted for addiction therapyRead full original descriptionShow less
Ketamine for combined depression and alcohol use disorder: A blinded randomized active placebo-controlled trial (the KeDA trial)
The primary objective is to assess the efficacy of ketamine for depression in adults with depression and AUD that are admitted for addiction therapy
Inclusion: 18-65 years of age; At least moderate depression without psychotic features; Alcohol dependence as their primary substance use disorder; Must be admitted to the hospital for inpatient addiction therapy at one of the inpatient units at University Hospital of North Norway.
Exclusion: Previous anaphylactic reaction to the IMP or AMP; Current or past history of psychotic disorder; Liver failure or impariment of liver function; Significant chronic kidney failure; Significant chronic heart failure; Significant chronic respiratory failure; Not able to provide adequate informed consent; Illegal use of ketamine the last 6 months; Significant cardiovascular event during the last year.